Welcome to our dedicated page for Inmode news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode stock.
InMode Ltd. reports developments in medical-technology devices that use radiofrequency technology for minimally invasive and non-invasive aesthetic and medical procedures. Company updates commonly address product platforms and treatment categories for plastic surgery, dermatology, gynecology, otolaryngology and ophthalmology, including face and body contouring, medical aesthetics and women's health.
Recurring news also covers GAAP and non-GAAP financial results, consumables and service revenue, regional performance in the United States and Europe, margin trends, investor-conference participation, board-reviewed strategic matters and capital allocation actions such as ordinary-share repurchase programs.
InMode Ltd. (Nasdaq: INMD) has launched the EvolveX platform featuring Transform technology, designed for hands-free, non-invasive body transformation with zero downtime. The platform meets rising post-lockdown demand for non-surgical treatments, offering a unique all-in-one solution that remodels skin, treats fat, and sculpts muscles. EvolveX’s innovative features allow physicians to customize treatments addressing specific patient needs, promising consistent results. CEO Moshe Mizrahy emphasized the growing demand for such solutions, backed by InMode's strong R&D pipeline.
InMode Ltd. (Nasdaq: INMD) has launched the EmpowerRF Women's Wellness platform, designed to deliver advanced feminine wellness therapies. This multi-functional solution utilizes various complementary technologies to address a range of conditions such as pain relief, blood circulation, and urinary incontinence. CEO Moshe Mizrahy emphasized the company's commitment to addressing unmet needs in women's wellness, while North American President Shakil Lakhani highlighted InMode's ongoing investment in this market despite competitors withdrawing. The platform aims to improve women's quality of life through minimally invasive procedures.
InMode Ltd. (Nasdaq: INMD), a leader in medical technologies, announced its participation in key upcoming conferences. On August 12, Yair Malca, CFO, will engage in a virtual fireside chat at Canaccord Genuity's Growth Virtual Conference, while Moshe Mizrahy, CEO, joins him for a similar event at UBS Genomics 2.0 in Laguna Beach. Additionally, both executives will be available for one-on-one meetings at the Needham Virtual Med Tech Conference on August 16. For more details, visit InMode's events page.
InMode Ltd. (Nasdaq: INMD) reported a remarkable 184% increase in second-quarter 2021 revenues, reaching $87.3 million, driven primarily by its proprietary surgical technologies. GAAP net income surged to $40.9 million, up from $8.6 million in Q2 2020, with diluted EPS rising to $0.95. The company boasts a strong cash position of $332.9 million. Management's outlook for 2021 anticipates revenues between $305 million and $315 million, with non-GAAP EPS projected between $3.10 and $3.25. InMode is also launching a new platform, Empower, focused on women's health.
InMode Ltd. (Nasdaq: INMD) has announced expectations for its second-quarter 2021 financial results, to be released on July 28, 2021. Preliminary estimates indicate record revenue between $86.5 million and $87.0 million, and Non-GAAP earnings per diluted share in the range of $1.00 to $1.01. The company has also increased its full-year 2021 revenue guidance to between $305 million and $315 million, with a projected non-GAAP gross margin of 84% to 86%.
InMode Ltd. (Nasdaq: INMD), a leader in medical technology, announced that its CFO, Yair Malca, will present at the Jefferies Virtual Healthcare Conference on June 4 at 10:30 a.m. ET. Malca will also be available for one-on-one virtual meetings during the event. A live webcast of the presentation can be accessed here and will be archived for 30 days. InMode specializes in innovative RF technology for various medical fields, including plastic surgery and dermatology.
InMode Ltd. (Nasdaq: INMD) will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 26 at 10:00 a.m. ET. Key executives, including CEO Moshe Mizrahy and CFO Yair Malca, will engage in discussions and be available for one-on-one meetings. The live webcast can be accessed on InMode's investor relations site, with an archive available for 30 days post-event. InMode specializes in innovative medical technologies utilizing RF technology across various medical fields.
InMode Ltd. (Nasdaq: INMD) reported a robust first quarter for 2021 with revenues of $65.5 million, a 62% year-over-year increase. The company's GAAP net income surged to $26.6 million or $0.63 per diluted share, up from $6.4 million and $0.15 respectively in Q1 2020. The high performance was driven by increased demand for minimally invasive technologies, particularly consumables which tripled over the last year. For 2021, InMode anticipates revenues between $270 million and $280 million and non-GAAP EPS between $2.60 and $2.75.
InMode Ltd. (Nasdaq: INMD) announced it will release its Q1 2021 financial results on May 5, 2021. Preliminary estimates indicate revenue between $65.0 million and $65.4 million, with non-GAAP earnings per diluted share ranging from $0.65 to $0.67. The expected non-GAAP gross margin for 2021 is between 84% and 86%. A conference call is scheduled for the same day at 8:30 a.m. ET to discuss these results. InMode specializes in innovative medical technologies, prominently using RF technology.
InMode Ltd. (Nasdaq: INMD) announced that key executives will present at the Needham 20th Annual Virtual Healthcare Conference on April 13, 2021, at 11:45 am EDT. The presentation will include insights from Mr. Moshe Mizrahy, Dr. Michael Kreindel, Mr. Yair Malca, Dr. Spero Theodorou, and Mr. Shakil Lakhani. Following the presentation, management will be available for one-on-one investor calls. A live webcast of the presentation will be accessible on the company's investor page, archived for 90 days. InMode specializes in innovative medical technologies, focusing on minimally-invasive RF devices.